May 21, 2014
TissueTech™ Inc Hosts Ribbon Cutting Ceremony For Its State of the Art Biotechnology Facility
-First of its kind facility in Doral dedicated to biotechnology product manufacturing –
Doral, Fla., May 21, 2014 – TissueTech™ Inc, a leader in regenerative wound healing therapies, recently announced the completion of its Phase I facility expansion of a state of the art biotechnology manufacturing cleanroom facility in Doral. This facility is the first of its kind in the City of Doral.
TissueTech™ hosted a ribbon cutting ceremony on Tuesday, May 13th from 4:30 p.m. – 5:30 p.m., located at 8305 N.W. 27th Street, Suite 101, Doral. The state of the art facility has over 4,500 square feet (ISO Class 7 Cleanroom) dedicated to biotechnology product manufacturing and over 5,500 square feet dedicated to good manufacturing practices (GMP) and logistics. Amy Tseng, President and CEO, and Dr. Scheffer Tseng, Chairman and Chief Scientific Officer, TissueTech™ Inc hosted the ceremony joined by distinguished guests including Mayor Luigi Boria.
“We are very excited about this latest achievement in the evolution of our company and proud to be the first biotechnology company to bring our manufacturing and corporate offices to Doral,” said Amy Tseng, President and CEO, TissueTech™ Inc “This state of the art biotechnology facility will help us to continue to grow and add to our talented and diverse workforce as well as contribute to the South Florida Community.”
TissueTech™ offers its portfolio of amniotic membrane and umbilical cord-based tissue and device products through its commercial entities: BioTissue® Inc, the industry leader in regenerative tissue therapies for ocular surface diseases and disorders, and Amniox® Medical, a leading technology provider to the musculoskeletal and wound care markets.
Founded in 2001 by Amy Tseng, President and CEO, and Dr. Scheffer Tseng, Chairman and Chief Scientific Officer, TissueTech™ Inc is a leader in regenerative amniotic tissue-based products for use in the ophthalmology, optometry, musculoskeletal and wound care markets. The National Institutes of Health (NIH) has supported research by TissueTech™ with more than 25 continuous years of research grants. Since inception, over 150,000 human implants have been conducted using the Company’s patented CryoTek® process and 300 peer-reviewed scientific publications have been produced supporting the technology platform. The Company has pioneered the clinical application of human amniotic membrane and its role in stem cell research. The Company’s first product, AmnioGraft®, is the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing while suppressing scarring and inflammation.